Accessability Links
Cookies on our website
By continuing to use this website we will assume you are happy to receive cookies as outlined in our cookie policy
Accept Policy

Phase II - III

Planning management, execution & analysis of Phase II-III clinical trials

We specialise in planning management, execution and analysis of Phase II-III clinical trials. These range from small studies to more complex multinational projects.

Within this we provide customised services, which can be deployed either on an individual basis or as part of a fully integrated service. These services can be used to support both global and locally managed projects and work across Clinical Operations, Medical and Safety Services, Regulatory Affairs, Data Management, Biostatistics, Interactive Technologies and Strategic Consultancy.


Martin Clarke on his role as Senior Project Management at ICON...
Our Clinical Research team apply their expertise in therapeutic, regulatory and operational areas to constantly rise to the challenge of solving any and all issues that may arise during a clinical project.

 

We cover all areas of medical and safety services and understand the needs of our clients on the importance of sound regulatory strategies. We work hard to deliver high-quality, cost-effective solutions that ensure the successful management and delivery of clinical trial data.

We provide biostatistic services for clinical development plans among others. Our interactive technologies have been carefully created, put in place and controlled to increase the accuracy of conducting global clinical studies. Our comprehensive expertise in scientific and operational areas by our Lifecycle Sciences group offers the finest strategic consultancy available within the industry.

Please click here to learn about the different job opportunities that we currently have available.

Services
ICON News
Clinical Research Management Jobs ICON Careers are a specialist Recruitment Agency, currently recruiting to fill vacancies across the ... Read more
ICON Awarded Best CRO at World Vaccines Congress 2014 ICON plc, is pleased to announce that it has been named Best Clinical Research Organisation i... Read more
ICON Reports Fourth Quarter 2013 Revenue of $345 million, up 15% year on year and EPS of 53c, up 56% ICON Reports Fourth Quarter 2013 Revenue of $345 million, up 15% year on year and EPS of 53c, up 5... Read more
 

Back to Top